The Era Of Generics By Shaji July 2009

David against Goliath! or the era of g e n e r i c s ,[object Object],[object Object]

GENERIC DRUGS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Growth of Global Market of g e n e r i c s 1998 – 2008 Turn over in USD Billion

Country wise g e n e r i c s’ Share in the Global Pharma Market - 2008 18,3 14,27 OTHERS 7,4 3,5 2,73 SPAIN 12 3,9 3,04 ITALY 29 4,4 3,43 TURKEY 28 5,8 4,52 CANADA 20,3 6,1 4,76 GREAT BRITAN 13,6 6,9 5,38 FRANCE 37 8,7 6,79 GERMANY 69 42,4 33,07 USA Generic Share in the Domestic Market % Generic Share in the Global Market % Generics Share in the Global Market USD Billion Country

the total generic turn over touched $78 billions by 2008, which is 18-20% of the pharma market of leading developed countries. ,[object Object],[object Object],[object Object],[object Object]

Growth of g e n e r i c s in Billion USD

Collaborations in the generic sector 2005-2007 736 Marix USA Mylan USA 4 900 Merck generics Ger Mylan USA 2007 230 Makiz Russia Stada Germany 324 Therapia Romania Ranbaxi India 494 Hemofarm Serbia Stada Germany 615 Betapharm Ger Dr. Reddys India 1 900 Andrx USA Watson USA 2 550 Pliva Croatia Barr USA 2006 not declared Heumann Germany Torrent India 5 650 Hexal/EON Labs Germany Novartis Swiss 2005 deal value Mill USD seller buyer year

? Actavis Island ? Ratiopharm Germany 2 150 Stiefel Lab USA GlaxosmithKline GB Kendrik Mexico Sanofi Aventis France 500 Medley Brazil Sanofi Aventis France 925 EBEWE Swiss Sandoz 2009 Collaborations in the generic sector 2008 & 2009 1 800 Zentiva Czech Sanofi Aventis France 4 600 Ranbaxi India Daiichi Sankyo Japan 7 500 Barr USA TEVA Israel 2008 deal value Mill USD seller buyer year

The g e n e r i c s GiANTS! 43 650 29 005 24 028 TOTAL 1 682 1 557 1 381 Japan Daichi-Ranbaxi 1 950 1 740 1 339 Island Actavis 2 139 2 033 1 569 Ger STADA Turn over Million USD Country Company 2 535 2 496 1 979 USA Watson 2 565 2 436 2 136 Ger Ratiopharm 5 137 2 166 1 257 USA Mylan 7 557 7 169 5 959 Swiss Sandoz 11 085 9 408 8 408 Israel TEVA 2006 2007 2008

the BIG pharma ,[object Object],[object Object],[object Object],[object Object]

Strategy of Pfizer ,[object Object],[object Object]

75 Indian Generics for US ,[object Object],[object Object],[object Object],[object Object],[object Object]

Transnational Giants are not ready to spare potential of post patent molecules to Generic Manufacturers! ,[object Object],[object Object]

Strategic steps of the BIG PHARMA! ,[object Object],[object Object]

Steps of the BIG PHARMA! ,[object Object],[object Object]

Target of the BIG PHARMA! ,[object Object],[object Object],[object Object]

More Volume and Less Margin is the key to success and growth of the future Generic Market ,[object Object],[object Object],[object Object]

The Asian and Indian factors ,[object Object],[object Object],[object Object],[object Object]

R E S U M E ,[object Object],[object Object],[object Object],[object Object],[object Object]

The Era Of Generics By Shaji July 2009

Recommended

Recommended

More Related Content

What's hot

What's hot (15)

Viewers also liked

Viewers also liked (17)

Similar to The Era Of Generics By Shaji July 2009

Similar to The Era Of Generics By Shaji July 2009 (20)

The Era Of Generics By Shaji July 2009